1,815 results on '"Denkert, Carsten"'
Search Results
2. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective
3. AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication
4. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
5. GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer
6. New treatment options for metastatic HER2-low breast cancer: Consequences for histopathological diagnosis
7. Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Tissue
8. Personalisierte Medizin – von der Translation zur Klinik
9. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
10. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy
11. PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine Neoplasms
12. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer—Development of Recommendations for Optimal Assay Performance
13. High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
14. The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy
15. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
16. Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma
17. Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom
18. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
19. Automated Scoring of Nuclear Pleomorphism Spectrum with Pathologist-level Performance in Breast Cancer
20. Immunhistologie in der Mammadiagnostik: Strategien für effiziente Diagnostik
21. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)
22. Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images
23. LRP1B—a prognostic marker in tubo-ovarian high-grade serous carcinoma
24. Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer
25. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus
26. Neue Therapiemöglichkeiten beim metastasierten HER2-low-Mammakarzinom: Konsequenzen für die histopathologische Diagnostik
27. pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas—proposal for a new pT3a/pT3b subclassification
28. Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood
29. Matrix stiffness drives stromal autophagy and promotes formation of a protumorigenic niche
30. Prädiktive molekulare Diagnostik beim Mammakarzinom: Welche Anforderungen stellen sich heute und in Zukunft für die Pathologie?
31. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials
32. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer
33. Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.
34. Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).
35. Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients
36. How VEGF-A and its splice variants affect breast cancer development – clinical implications
37. Towards computational fluorescence microscopy: Machine learning-based integrated prediction of morphological and molecular tumor profiles
38. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
39. Prioritization of metabolic genes as novel therapeutic targets in estrogen-receptor negative breast tumors using multi-omics data and text mining
40. Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
41. DNA methylation-based classification of sinonasal tumors
42. Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer
43. EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
44. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
45. Mesenteric fibrosis in patients with small intestinal neuroendocrine tumors is associated with enrichment of alpha‐smooth muscle actin‐positive fibrosis and COMP‐expressing stromal cells
46. Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
47. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
48. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
49. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
50. Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie: 17. Internationale St.-Gallen-Konsensuskonferenz vor dem Hintergrund deutscher Therapieempfehlungen diskutiert
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.